The authors wish to thank the Swiss National Science Foundation (MD-PhD Grant 323530_199395), the Janggen-Pöhn-Stiftung and the AlumniMedizin Basel for their financial support of this project. In addition, the researchers would like to thank all the participants who volunteered for this study.
Disclosure: P. Valmaggia, Swiss National Science Foundation (Grant 323530_199395) (F), the Janggen-Pöhn Stiftung (F), AlumniMedizin Basel (F), Heidelberg Engineering GmbH (I); P.C. Cattin, None; R. Sandkühler, None; N. Inglin, None; T.P. Otto, Heidelberg Engineering GmbH (E); S. Aumann, Heidelberg Engineering GmbH (E); M.M. Teussink, Heidelberg Engineering GmbH (E); R.F. Spaide, Topcon Medical Systems (C), Roche (C), Bayer (C), Heidelberg Engineering (C), Genentech (C); H.P.N. Scholl, Swiss National Science Foundation (Project funding: “Developing novel outcomes for clinical trials in Stargardt disease using structure/function relationship and deep learning” #310030_201165, and National Center of Competence in Research Molecular Systems Engineering: “NCCR MSE: Molecular Systems Engineering (phase II)” #51NF40-182895) (F), the Wellcome Trust (PINNACLE study) (F), and the Foundation Fighting Blindness Clinical Research Institute (ProgStar study) (F), Scientific Advisory Board of Boehringer Ingelheim Pharma GmbH & Co. (S), Droia NV (S), Eluminex Biosciences (S), Janssen Research & Development, LLC (Johnson & Johnson) (S), Novartis Pharma AG (CORE) (S), Okuvision GmbH (S), ReVision Therapeutics Inc. (S), Saliogen Therapeutics Inc. (S), Alnylam Pharmaceuticals Inc. (C), Gerson Lehrman Group Inc. (C), Guidepoint Global, LLC (C), and Intergalactic Therapeutics Inc. (C), Data Monitoring and Safety Board/Committee of Belite Bio (DRAGON trial, NCT05244304, LBS-008-CT02, NCT05266014), (CT2019-CTN-04690-1) (S), F. Hoffmann-La Roche Ltd. (VELODROME trial, NCT04657289; DIAGRID trial, NCT05126966; HUTONG trial) (S), member of the Steering Committee of Novo Nordisk (FOCUS trial; NCT03811561) (S); P.M. Maloca, F. Hoffmann-La Roche Ltd. (C), MIMO AG (O), VisionAI (O). Funding organizations had no influence on the design, performance or evaluation of the current study